Media
News
Quotient Limited Announces SARS-CoV-2 (COVID-19) Antibody Test Final Performance Data

JERSEY, Channel Islands, April 27, 2020 (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company (the Company), headquartered in Eysins, Switzerland, today reported very strong final study performance data for its SARS-CoV-2 antibody test.

Quotient Limited Announces SARS-CoV-2 (COVID-19) Antibody Test Performance Update

JERSEY, Channel Islands, April 21, 2020 (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company (the Company), headquartered in Eysins, Switzerland, today reported positive performance data for its SARS-CoV-2 antibody test.

The Times UK: Antibody tests and 'mass diagnosis'

Mass diagnosis ‘available now’

CNN Money CH: Swiss company races to bring COVID-19 antibody tests to market

Experts say antibody testing will play a crucial role in easing coronavirus lockdowns around the world and reviving economies.

Financial Times: Swiss group says its machines can conduct 30m virus antibody tests this year

Quotient warns global shortages of critical components could hamper efforts

To read the full article, visit: Financial Times

Quotient Limited Announces the Completion of the SARS-CoV-2 Antibody Test Development

JERSEY, Channel Islands, April 06, 2020 (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company (the Company), headquartered in Eysins, Switzerland, today announced the completion of the development phase of a microarray based SARS-CoV-2 (COVID-1

Quotient Limited to Host Investor Information Conference Call and Live Webcast
Quotient Limited Announces CE Mark Approval for Initial Serological Disease Screening Microarray

JERSEY, Channel Islands, Feb.

Quotient Limited to Report Third Quarter 2020 Financial Results and Host Conference Call

JERSEY, Channel Islands, Jan. 21, 2020 (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company, today announced that financial results for its fiscal third quarter ended December 31, 2019, will be released before market open on Thursday, January 30, 2020.

Quotient aims to reduce blood testing time

C’est une revolution dans l’univers de l’analyse de sang. Quotient, une société basée à Eysins (VD), aux portes de Nyon, met sur le marché une nouvelle technique qui permet d’obtenir des résultats complets d’un échantillon avec une grande rapidité.